Background and purpose: Evidence for effective treatment options for orthostatic hypotension (OH) in Parkinson's disease (PD) is scarce. Elevation of cholinergic tone with pyridostigmine bromide has been reported as a way to improve blood pressure (bp) regulation in neurogenic hypotension without causing supine hypertension. Methods: This was a double-centre, double-blind, randomized, active-control, crossover, phase II non-inferiority trial of pyridostigmine bromide for OH in PD (clinicaltrials.gov NCT01993680). Patients with confirmed OH were randomized to 14 days 3 9 60 mg/day pyridostigmine bromide or 1 9 0.2 mg/day fludrocortisone before crossover. Outcome was measured by peripheral and central bp monitoring during the Schellong manoeuvre and questionnaires. Results: Thirteen participants were enrolled between April 2013 and April 2015 with nine participants completing each trial arm. Repeated measures comparison showed a significant 37% improvement with fludrocortisone for the primary outcome diastolic bp drop on orthostatic challenge (baseline 22.9 AE 13.6 vs. pyridostigmine bromide 22.1 AE 17.0 vs. fludrocortisone 14.0 AE 12.6 mmHg; P = 0.04), whilst pyridostigmine bromide had no effect. Fludrocortisone caused an 11% peripheral systolic supine bp rise (baseline 128.4 AE 12.8 vs. pyridostigmine bromide 130.4 AE 18.3 vs. fludrocortisone 143.2 AE 10.1 mmHg; P = 0.01) but no central mean arterial supine bp rise (baseline 107.2 AE 7.8 vs. pyridostigmine bromide 97.0 AE 12.0 vs. fludrocortisone 107.3 AE 6.3 mmHg; P = 0.047). Subjective OH severity, motor score and quality of life remained unchanged by both study interventions. Conclusions: Pyridostigmine bromide is inferior to fludrocortisone in the treatment of OH in PD. This trial provides first objective evidence of the efficacy of 0.2 mg/day fludrocortisone for OH in PD, causing minor peripheral but no central supine hypertension. In addition to peripheral bp, future trials should include central bp measurements, known to correlate more closely with cardiovascular risk.
Introduction
The disease burden by autonomic dysfunction in Parkinson's disease (PD) is increasingly recognized. Orthostatic hypotension (OH) is reported to have an incidence of around 30% in PD [1] and a particularly high influence on quality of life [2] , whilst there is only class III evidence for therapeutic interventions [3] . Current treatment strategies anchor at behavioural adaptations, increasing overall blood pressure (bp) by elevation of plasma volume or administering vasoactive agents [4] . Until now, however, all of these interventions for OH in PD are viewed as investigational [5] , reflecting the lack of randomized controlled trials.
In addition to decreased cardiovascular sympathetic innervation [6] , impaired baroreflex function is a major factor for OH in PD [7] . Elevation of cholinergic tone by pyridostigmine bromide (PB) has been suggested to strengthen both limbs of the baroreflex without causing supine hypertension [8] . The results from a trial in a cohort of patients with neurogenic OH were promising [8] . The aim was therefore to study the effect of PB on OH in a PD cohort. A noninferiority design was chosen with fludrocortisone (FC), a synthetic mineralocorticoid widely available and used, as an active comparator. Open-label studies in small samples have suggested that FC improves OH in multiple system atrophy (MSA) [9] and in levodopa induced OH [10] , whilst the only randomized controlled trial in PD showed an effect on subjective OH symptom severity but not bp measurements [11] .
Methods
This double-centre, double-blind, randomized, activecontrol, crossover, phase II non-inferiority trial was conducted in accordance with national and international law and good clinical practice. It was registered locally and internationally (clinicaltrials.gov NCT01993680). The study protocol was approved by the Zurich Cantonal Ethics Committee and the national medical regulatory body Swissmedic. All participants provided written informed consent for participation prior to inclusion. The study was designed with diastolic bp drop on Schellong manoeuvre (mmHg) as the primary outcome measure. Power calculations were based on effect sizes for PB in neurogenic OH [8] with a non-inferiority margin M of 50%. For an effect size of 2.45 and a calculated error probability of a = 0.05 (resulting power 1 À b = 0.95), an overall sample size of n = 10 participants was calculated to prove non-inferiority (critical t 1.86; actual power 0.97); to increase power, our aim was n = 18.
Participant selection
Parkinson's disease patients diagnosed according to UK Brain Bank criteria, 50-80 years of age, Hoehn and Yahr stages 2 and 3, with symptomatic, established OH (≥20 mmHg drop systolic or 10 mmHg diastolic peripheral bp within 3 min of standing [12] ) on routine follow-up were recruited from the outpatient clinics of participating centres. Patients on medication influencing bp regulation (antihypertensive drugs, mirtazapine, sertraline, paroxetine, fluoxetine, venlafaxine, trazodone, anticholinergics etc.), depolarizing muscle relaxants, with systemic disease (diabetes, infection, renal or kidney failure, malignancy), pathological underweight or overweight and conditions interfering with compliance were excluded. Furthermore, patients presenting with signs for cerebellar involvement or other clinical or imaging features suggestive of MSA were not included. Participants continued their dopaminergic medication and physical hypotension measures unchanged throughout the study.
Trial design and procedures
Study visits were conducted directly before the first and directly after the final dose of trial medication. Trial arms had 14 days duration and 21 days of washout before crossover, with the biological half-life being 36 h (FC) and 1.5 h (PB) respectively. All study visits included the same procedures and were conducted in the same clinical trial suite at ambient room temperature from 9 am after an overnight fast. Investigations were performed after a minimum of 20 min supine rest at 30°head elevation. Non-invasive central bp measurements were performed using pulse wave analysis by applanation tonometry [13] (SphygmoCor, AtCor Medical Pty, Sydney, NSW, Australia); measurements with an operator index <80% were excluded. Cardiovascular monitoring was recorded continuously during the Schellong manoeuvre (Nihon Kohden, Cham, Switzerland; 10 min supine, 10 min standing). Motor (United Parkinson's Disease Rating Scale part III), cognitive (Montreal Cognitive Assessment) and additional domain assessments [Hospital Anxiety and Depression Scale, Zurich autonomic questionnaire, Orthostatic Hypotension Severity Assessment (OHSA) scale [14] and quality of life] were recorded in a standardized way. Home bp measurements in a sitting position consisted of automated, repeat morning and evening measurements (WatchBPhome, microlife, Widnau, Switzerland) for 7 days before study visits.
Study medication was prepared in identical capsules by the Cantonal Pharmacy of the Canton of Zurich, which also performed independent randomization. Study medication was kept at 4°C by participants and was started at 3 9 30 mg/day (PB) and 1 9 0.1 mg (FC) + 2 9 placebo/day for 3 days before dose increment to 3 9 60 mg/day and 1 9 0.2 mg/day + 2 9 placebo/day.
Compliance was monitored by drug calendars and collection of empty medication packaging.
Data analysis
All data are expressed as means and standard deviations. Datasets were included if trial arms were completed. Mixed linear model statistics were used for repeated measures comparison. Post hoc analysis (least significant difference) was performed in the case of significant differences between groups. A two-tailed P value of 0.05 was considered significant. Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY, USA).
Results
Thirteen participants were enrolled between April 2013 and April 2015 -for clinical characteristics see Table 1 . Before the final study visit, two subjects withdrew consent due to strenuous study procedures, one received deep brain stimulation implantation and one dropped out due to a non-study-related accident. After an interim analysis of the primary outcome measure after the ninth completed dataset (subject 13) showing futility of the primary outcome measure for PB, the trial was terminated and data were analysed as intention to treat. Each trial arm was fully completed by nine participants and medication compliance was 99%. The pre-defined non-inferiority margin M was missed and non-inferiority was rejected.
Outcome variables of the intention-to-treat analysis are displayed in Table 2 and Fig. 1 . FC improved the primary outcome measure diastolic bp drop on Schellong manoeuvre by 37% (P = 0.016), as well as minimal mean arterial bp standing by 15% (P = 0.02), whereas PB treatment had no significant effect (Fig. 1a, b) . Subjective symptom severity was not changed by any intervention (Fig. 1e) and did not correlate with changes in bp drop on Schellong (ns). Peripheral systolic bp supine (Fig. 1c) and systolic 7 day home bp measurement sitting were increased by 11% after FC (P = 0.004) but not PB treatment. Central mean supine bp was lowered by 9% by PB (P = 0.03) but remained unchanged after FC treatment (Fig. 1d) . Neither drug had any influence on motor, cognitive and neuropsychiatric measure or quality of life. Stool consistency was significantly softened with PB treatment (P = 0.015), whilst neither treatment had an influence on the subjective severity of other autonomic symptoms. Whilst PB lowered sodium levels (P = 0.009), potassium levels were unchanged in both trial arms (Fig. 1f, g ).
Transient, mild adverse events were reported during PB (dizziness, n = 1; mouth dryness, n = 1; transient increase of motor OFF phase, n = 1) and FC treatment (leg oedema, n = 1) without leading to dose adjustment or dropout.
There was a weak positive correlation between motor and subjective OH symptoms amongst participants ( Fig. 1h ; r 2 = 0.38, P = 0.03).
Discussion

Futility of pyridostigmine bromide for OH in PD
Orthostatic hypotension is classically defined by a drop of more than 20 mmHg in systolic or 10 mmHg in diastolic peripheral bp within 3 min of standing [29] ); bp, blood pressure; OHSA, Orthostatic Hypotension Severity Assessment. [12] . Recently a mean bp (MBP) <75 mmHg upon standing has been found to correlate better with OH symptoms in PD [15] . In the present study, PB failed to display a positive effect for both OH definitions as well as for the subjective severity of OH symptoms in PD patients. Whilst 55% of patients had a net improvement of diastolic bp drop with PB (100% for FC, P = 0.08), the overall mean effect size was negligible and did not reach the pre-set non-inferiority margin. Thus, in our homogeneous PD cohort, the positive effect of PB on OH could not be reproduced, as shown for a single dose of 60 mg in a mixed cohort of patients with neurogenic OH [8] ; follow-up studies of the initial report did not include PD patients [16, 17] . Possible explanations for this discrepancy could be either insufficient dosing or age-and diseaseinherent factors. Previous studies have reported an effect of 30 mg [18] , 120 mg [19] and 180 mg [20] of PB on autonomic nervous system activity in healthy controls. It cannot be excluded that 180 mg/day PB was insufficient for elevation of cholinergic tone in this population. On the other hand, the significant subjective softening of stool consistency and increased heart rate change on Schellong manoeuvre by PB suggests a clinically relevant effect on the autonomic nervous system. Alternatively, different OH disease mechanisms might influence the effect of PB on the baroreflex. The lesion site leading to OH is central and pre-ganglionic in MSA, whereas it is peripheral and post-ganglionic in pure autonomic failure and PD [21] . So far no difference in baroreflex testing has been reported between MSA and PD [22] , suggesting that further studies into the exact pathophysiological mechanism of baroreflex dysfunction in these aetiologies are warranted.
Our results indicate that a reasonable therapeutic effect on OH in PD might not be achievable with PB. Furthermore, the finding of hyponatraemia is an additional caveat for its long-term application in PD, although the exact mechanism underlying this phenomenon remains elusive.
Beneficial effect of fludrocortisone
In contrast, our data provide the first evidence for a significant improvement in both diastolic bp drop on orthostatic challenge (À37%) and MBP standing (+15%) by 0.2 mg/day FC in PD. As MBP and diastolic bp have been shown to correlate more closely with symptomatic OH than systolic bp [15] , OH therapy with FC can thus be considered successful. So far a significant effect has only been shown in cohorts of diabetic OH and ShyÀDrager syndrome, i.e. MSA [9, 23] . In the single previous trial of FC for OH in PD, 0.1 mg/day FC only improved subjective symptoms but changed neither bp drop on orthostatic challenge nor supine systolic bp [11] . Together with our observations this supports a dose-dependent effect of FC on bp regulation. The fact that this positive effect with 0.2 mg/day FC on objective bp regulation was not reflected by significant changes of subjective OH symptom perception might be due to the limited sample size, the low sensitivity of the OHSA score or a possible dissociation of subjective versus objective OH symptoms in this population [24] .
Treatment effects on central blood pressure
As expected, 0.2 mg/day FC caused an overall increase of peripheral bp levels -systolic bp in sitting and supine position was raised by 11%. According to suggested criteria, this constitutes supine hypertension [15] , quoted to be the most relevant side effect of FC treatment [4, 15] . Although frequently quoted, there is no clear definition of supine hypertension, leading to different cut-off values applied to study data in the literature [15, 25] . Our finding of unchanged central bp with FC treatment, however, sheds light on another, novel aspect in the interpretation of supine hypertension in PD. The elastic properties of the arterial system and its branches cause the central bp to be amplified in the periphery and, whilst the bp in the central arteries directly governs the load on the heart, this is not directly reflected by the peripheral bp [26] . There is compelling empirical evidence showing that central bp is superior in predicting cardiovascular disease risk in comparison to peripheral bp [26, 27] . To our knowledge, central bp has not been reported in PD patients before [11, 16, 25] . Although further studies into central bp in PD therefore seem warranted, the finding of unchanged central bp under FC treatment might indicate a more favourable side effect profile than anticipated. In contrast to previous reports, no electrolyte disturbances and in particular hypokalaemia were observed with FC use.
Limitations and conclusion
It is acknowledged that the number of participants and dropout rate in this trial is a weakness and thus replication is warranted. Future trials with similarly strict inclusion and exclusion criteria will probably need a multi-centre approach [25] , as recruitment was more difficult than anticipated. Although alternative pharmacological influence on bp was excluded, dopaminergic medication of course influenced bp regulation [28] . However, measurements in the OFF state were deemed unfeasible and measurements in the ON state were considered to more closely resemble clinical reality. Independent of this it is important that pharmacological therapy of OH should always be preceded by the exhaustion of non-pharmacological measures. This trial, however, provides first evidence for the efficacy of 0.2 mg/day FC for OH in PD, which is a confirmation of frequent clinical practice. The observed effect size with FC treatment is of note compared to recent much larger trials for OH in PD that did not show a persistent benefit on bp regulation [25] . First evidence that supine hypertension in the periphery might not reflect central bp changes in PD is also shown. Additional studies are needed to clarify the significance of central bp and supine hypertension in cardiovascular risk assessment in PD.
